Ebola vaccine trial targets HIV-Positive adults and teens

NCT ID NCT03031912

Completed ⭐️ VACCINE ⭐️ Sponsor: Canadian Immunization Research Network Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental Ebola vaccine (V920) in 251 HIV-infected adults and adolescents to see if it is safe and triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels. The trial took place in Canada and Africa, with results helping to determine if the vaccine can protect people with HIV from Ebola.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: V920 (rVSVΔG-ZEBOV-GP) Ebola virus vaccine
What this could lead to: If successful, this could show that the Ebola vaccine is safe and effective for people living with HIV, expanding protection to a vulnerable group.
What could go wrong: This is a phase 2 trial with 251 participants, so results are still early. The vaccine may not produce a strong immune response in all HIV patients, and side effects like fever or joint pain are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBOLA

Contacts and locations

Locations

CHUM

Montreal, Quebec, H2X 0A9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.